

Usefulness of Baseline Neutrophil to Lymphocyte Ratio (NLR) in Hematological Malignancies

Burak Uz*

Gazi University Faculty of Medicine, Department of Internal Medicine, Division of Adult Hematology

Abstract: Systemic inflammatory response was reported to be a poor prognostic factor in several malignancies. An inexpensive and readily available laboratory tool, neutrophil to lymphocyte ratio (NLR), can be easily obtained from differential blood counts. Current evidence suggests that a baseline NLR may predict the long-term survival results of patients with lymphoproliferative diseases (especially diffuse large B-cell lymphoma). The relationship between systemic inflammation and cancer, and the usefulness of NLR in hematological malignancies will be discussed in this comprehensive review.

Keywords: Neutrophil to lymphocyte ratio, Inflammation, Cytokines, Cancer, Metastasis, Predictive, Prognosis.

INTRODUCTION

Neutrophil to lymphocyte ratio (NLR), calculated from complete blood count with differential, may reflect and clarify the immune response in systemic inflammatory states [1]. NLR has been reported as an independent prognostic marker in solid [2] and hematological malignancies [3]. However, the number of studies about the use of NLR on the long-term results of hematological malignancies are quite a few when compared to those carried out with solid tumors. In this review, the basic mechanisms of inflammation, cancer development, and their relationship between NLR will be discussed. Additionally, the clinical use of NLR in hematological malignancies including classical Hodgkin lymphoma (HL), diffuse large B cell lymphoma (DLBCL), multiple myeloma (MM), and finally peripheral T-cell lymphoma will be reported in the light of current medical literature.

CANCER AND INFLAMMATION

A high NLR is associated with adverse outcomes in non-malignant conditions such as chronic inflammation in ischemic heart diseases [4], hepatic cirrhosis [5], and ulcerative colitis [6]. From this perspective, some researchers have demonstrated a positive correlation with NLR and known markers of systemic inflammation (*i.e.* erythrocyte sedimentation rate, C-reactive protein (CRP), fibrinogen) [1].

Cancer-related systemic inflammatory response can up regulate cytokines, chemokines and other inflammatory mediators [7]. About 25% of cancers are

associated with chronic inflammation [8, 9]. Although the exact mechanism between inflammation and cancer remains unclear, two main factors are suggested: “*extrinsic factors*” that cause an ongoing chronic inflammation, and “*intrinsic factors*” that alters the expression of inflammation-related pathways via oncogenes and/or tumor suppressor genes [8].

Tumor necrosis factor-alpha (TNF- α), interleukin (IL)-6 and IL-1 are the most commonly released inflammatory cytokines in the tumor microenvironment [7]. Plasma levels of TNF- α are elevated in patients with advanced cancer [10]. TNF- α produced either by host cells or malignant cells directly activate oncogenes and DNA damage, which in turn may contribute to an increased propensity for metastasis activity. One of its receptors, TNF receptor 2, is generally found on the recruited leukocytes [11].

Suppressed T-cell activity by neutrophils or immature myeloid cells, called myeloid-derived suppressor cells (MDSCs), was linked to immune deregulation in advanced cancer patients. The major cause of severe systemic T-cell suppression was thought to be induced by a neutrophil-derived effector molecule, H₂O₂ [12]. IL-8 induces exocytosis of arginase-1 by neutrophils in non-small cell lung cancer cell lines which inhibits T-cell proliferation by degrading extracellular arginine [13]. Arginase production from CD11b+, CD14-, CD15+ cells with polymorphonuclear morphology in metastatic renal cell carcinoma patients have been shown to be a mechanism of tumor evasion [14]. Matrix metalloproteinase (MMP)-9 predominantly expressed by bone marrow-derived CD-45 positive leukocytes contributes to the formation of a mature vasculature, resulting in angiogenesis and tumor progression in a murine neuroblastoma model [15].

*Address correspondence to this author at the Gökusu Mah, Erzurum Kongre Cad, Gökusu Metrokent Sitesi, A-3 Blok, No= 26, Eryaman, Ankara/Türkiye;
Tel: +90 (312) 202 55 79; Fax: +90 (312) 223 64 17;
E-mail: burakuz78@gmail.com

More recently, upregulated MMP-2 expression by ovarian cancer cells has been associated with the initial steps of metastasis [16]. CXCL1/macrophage inflammatory protein-2 (MIP-2) leads to acculation of murine neutrophils that, in turn, increase the production of vascular endothelial growth factor-A, resulting in angiogenesis *in vivo* [17].

Taken together, development of cancer still remains to be explained in terms of inflammation. However, there are growing evidence-based data supporting the critical role of cancer-related systemic inflammation on tumor cell survival and proliferation, angiogenesis, tumor invasion and progression.

WHY DO WE NEED A NOVEL PROGNOSTIC MARKER?

Prognostic models for hematologic malignancies that are inexpensive, readily available, easy to perform and interpret are needed in clinical practice, especially

in resource-poor countries. Besides the solid tumors, there is a growing interest about the use of NLR in an attempt to predict the long-term results of hematological malignancies. The core studies about this recent issue are listed in Table 1.

CLASSICAL HODGKIN LYMPHOMA

It has long been known that the baseline lymphocyte count has a prognostic role in classic Hodgkin lymphoma (cHL). Lymphopenia (<600 cells/ μ L or <8% of the white blood cell count) is related to adverse survival outcome [18], as well as tumor-infiltrating lymphocytes and tumor-infiltrating macrophages that constitute tumor microenvironment [19, 20].

The accumulation of neutrophils is thought to be related with increased cytokin levels, especially IL-8 [21]. By combined isotopic *in situ* hybridization and advanced immunohistologic studies, IL-8 expression is

Table 1: Core Clinical Studies About the Use of Neutrophil-to-Lymphocyte Ratio in Several Hematological Malignancies for Predicting Long-Term Results

References	Disease	n	NLR	Cut off NLR	Median Follow-Up	Clinical Value
Porrata <i>et al.</i> [3]	DLBCL	255	NS	3.5	59.1 months	Patients with a NLR ≥ 3.5 at diagnosis experienced inferior 5-year OS and PFS compared with patients with a NLR <3.5. A higher NLR at diagnosis was also associated with higher IPI scores, B-symptoms and LDH levels.
Troppan <i>et al.</i> [27]	DLBCL	290	NS	4	33.5 months	NLR ≥ 4 was associated with worse OS.
"	"	"	"	1.8	"	NLR ≥ 1.8 was associated with shorter DFS.
Keam <i>et al.</i> [28]	DLBCL	447	2.54 (0.03-94.0)	3	59.0 months	A pre-NLR ≥ 3 was independently related with poor OS and PFS in newly-diagnosed DLBCL patients treated with R-CHOP. Among patients who had an initially pre-NLR ≥ 3 , those whose NLR decreased to <3 after R-CHOP had significantly better OS and PFS than patients whose NLR remained high after R-CHOP.
Ho <i>et al.</i> [30]	DLBCL	148	4.25 \pm 3.63	4.35	53.28 months	NLR was found to be a prognostic tool of 5-year OS and 5-year PFS.
Melhardt <i>et al.</i> [31]	DLBCL	515	NA	5.54	53 months	NLR did not correlate with survival.
Koh YW <i>et al.</i> [23]	cHL	312	3.8 (0.09-29.67)	4.3	64 months	Patients with a NLR ≥ 4.3 at diagnosis experienced inferior 5-year OS compared with patients with a NLR <4.3, but did not differ in terms of EFS.
Kelkitli <i>et al.</i> [37]	MM	151	2.79 \pm 1.82	2	41 months	Patients with a NLR ≥ 2 at diagnosis experienced inferior 5-year OS and EFS compared with patients with a NLR <2.
Romano <i>et al.</i> [38]	MM	309	1.9 (0.4-15.9)	2	NS	In the era of novel anti-myeloma agents, patients with a NLR ≥ 2 at diagnosis experienced inferior 5-year OS and PFS compared with patients with a NLR <2.
Beltran <i>et al.</i> [39]	PTCL-U	83	2.5 (0.3-99)	4	NS	NLR ≥ 4 was associated with worse OS.

Abbreviations: NLR: Neutrophil to lymphocyte ratio; n: Number of patients; DLBCL: Diffuse large B-cell lymphoma; cHL: Classical Hodgkin lymphoma; MM: Multiple myeloma; PTCL-U: Peripheral T-cell lymphoma unspecified; OS: Overall survival; DFS: Disease-free survival; PFS: Progression-free survival; EFS: Event-free survival; IPI: International prognostic index; LDH: Lactate dehydrogenase; R-CHOP: Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; NS: Not stated, NA: Not available.

largely confined to reactive infiltrate cells and less frequently to Hodgkin and Reed-Stenberg cells, particularly in the nodular sclerosing subtype [22].

We could find only one study in the medical literature about the use of NLR in cHL [23]. In this retrospective analysis, 312 patients with cHL were enrolled and the median follow-up after diagnosis and NLR value were, 64 months and 3.8, respectively. Patients with NLR ≥ 4.3 at diagnosis were found to be more likely to present with anemia, lymphopenia, hypoalbuminemia, abnormal lactate dehydrogenase (LDH), presence of B symptoms, and advanced disease stage. In contrast, NLR did not correlate with age, treatment modality, chemotherapy regimen or the presence of Epstein-Barr virus. The patients with NLR ≥ 4.3 had significantly lower 5-year estimated overall survival (OS) than those patients with NLR < 4 (80.3% vs. 91.9%, $p = < .001$), but the groups did not differ in terms of event-free survival (EFS). The OS advantage was detected in only advanced-stage (stage IV) subgroups. In multivariate analyses NLR ≥ 4 was detected as an independent prognostic factor.

International Prognostic Score (IPS) is also an independent predictor and is used for risk stratification in HL [18]. Therefore, Koh *et al.* have combined NLR and IPS, "IPS-NLR". In low-risk IPS patients (IPS < 4), the patients with NLR ≥ 4 presented with worse OS than those with NLR < 4 . This difference was not noted in high IPS risk patients (IPS = 4). Nodular sclerosing was found to be the most common (56.7%) subtype in the aforementioned cohort. When the statistical analyses were reanalysed in nodular sclerosing subgroup alone, the predictive impact of a NLR value of ≥ 4 were ongoing in terms of OS (but not for EFS) [23].

DIFFUSE LARGE B CELL LYMPHOMA

NLR is most frequently investigated in patients with diffuse large B-cell lymphoma (DLBCL). Besides direct apoptosis against lymphoma cells and antibody-dependent cell cytotoxicity, another possible mechanism of action of rituximab is to target the inflammatory component of the tumor by causing neutropenia [24] and direct inhibition of signal transducer and activator of transcription-3 [25] and nuclear factor kappa-B [26].

Firstly, Porrata *et al.* have investigated the possible predictive effect of NLR on survival rates of 255 DLBCL patients. With a median follow-up of 4 years, DLBCL patients with a NLR < 3.5 at diagnosis experienced a

superior OS (87% vs. 56%, respectively) and progression-free survival (PFS, 72% vs. 45%, respectively) compared to those patients with a NLR ≥ 3.5 at diagnosis. Multivariate analysis showed NLR to be an independent prognostic factor for OS and PFS. Extranodal disease, number of cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP), post-chemotherapy radiation therapy, and the reasons for post-chemotherapy radiation therapy was similar in both groups. A higher NLR was also associated with higher IPI scores and B-symptoms. The authors have also identified a positive correlation between NLR at diagnosis and LDH levels. NLR at diagnosis was an independent predictive factor besides stage for LDH production [3].

Afterwards, Troppan *et al.* have demonstrated that a high derived NLR at diagnosis of DLBCL significantly associated with poor outcome in terms of OS and disease-free survival (DFS) [27]. Similarly, a pre-NLR ≥ 3 was independently related with poor OS and PFS in newly-diagnosed DLBCL patients treated with R-CHOP. In patients with high pre-NLR, reduction of the post-NLR < 3 after R-CHOP treatment was correlated with improved survival. When adding pre-NLR to the IPI score, survival prediction and risk stratification were improved. Moreover, low pre-NLR (< 3) was associated with a higher number of peripheral CD19⁺ lymphocytes and natural killer cells [28]. Although, these two studies [27, 28] were retrospective, they have had large number of DLBCL patients (290 and 447, respectively).

Chang *et al.* [29] have compared peripheral blood samples of 77 patients with DLBCL and 30 healthy controls. The patients with DLBCL had significantly higher percentages of neutrophils, and lower percentages of lymphocytes compared to control patients. In univariate analysis, high neutrophil counts ($\geq 6,000/\mu\text{L}$) were found to be a poor prognostic factor for survival in addition to high IPI scores. And finally, in a retrospective analysis including 148 newly-diagnosed DLBCL patients, the NLR was found to be a prognostic tool of 5-year OS and 5-year PFS by univariate analyses [30].

In contrast to these hopeful results, in a very recent retrospective analysis including 515 patients with DLBCL, NLR did not correlate with survival [31], as well as high gamma-glutamyl transferase levels, and platelet to lymphocyte ratio. In multivariate analyses, anemia, high C-reactive protein and high bilirubin levels had an independent prognostic value for survival in

addition to the National Comprehensive Cancer Network-International Prognostic Index (NCCN-IPI) score.

MULTIPLE MYELOMA

MM is a clonal disorder characterized by the proliferation of plasma cells and their accumulation within the bone marrow. Age, performance status, serum β_2 -microglobulin level, the hemoglobin level, the presence of circulating plasma cells, plasmablastic morphology, the plasma cell proliferation status (detected either by plasma cell labeling index or flow cytometry) are well-known prognostic factors in MM. Additionally, in some reports, a low platelet count, hypercalcemia, and a low serum albumin level have associated with poor prognosis [32]. Given the disease heterogeneity and the dynamic process of the disorder, it is sometimes not possible to predict the prognosis of patients exactly.

International Staging System (ISS) is a worldwide-accepted classification system based on serum albumin and β_2 -microglobulin levels [33]. The patients should be divided into 3 subgroups according to the ISS, with median survival varying from 62 months (stage I) to 29 months (stage III). Although ISS is inexpensive and readily available, it does not take into account the cytogenetic profile of the patients and the role of bone marrow microenvironment. Additionally it was validated retrospectively on patients treated prior to the advent of novel anti-myeloma agents including proteasome inhibitors (bortezomib, carfilzomib), immunomodulators (lenalidomide, pomalidomide), or their combinations. Therefore, the investigators have tried to enhance the performance of the ISS by adding other soluble markers or genetic risk features [34-36].

In a retrospective analysis including 151 patients with MM [37], mean NLR was significantly higher in patients with MM than age- and gender- matched healthy controls (2.79 ± 1.82 vs. 1.9 ± 0.61). Patients with $\text{NLR} \geq 2$ had significantly higher serum CRP levels, more frequent renal impairment, and more advanced ISS stage. In addition, NLR is independently associated with long-term results of MM patients. After a 41 months follow-up, 5-year estimated OS and event-free survival (EFS) rates were significantly lower in patients with a $\text{NLR} \geq 2$ (42.4% vs. 87.5%) compared to those with a $\text{NLR} < 2$ (41.8% vs. 88.4%). On the other hand, mean lymphocyte counts, bone marrow infiltration ratio by plasma cells, treatment regimens, and autologous stem cell transplantation rates were

found to be similar between the groups in terms of NLR. A major limitation of this retrospective analysis was that the limited use of initial cytogenetic analysis which is a prognostic parameter that affects long-term survival rates of MM patients [34-36]. Cytogenetic data were available for only 34.4% of the cases. Among these patients 44.2% of them had cytogenetic abnormalities and the most frequent (30.7%) adverse chromosomal abnormality was reported as $\text{del}(13q)$ [37].

More recently, Romano *et al.* [38] have investigated the predictive value of initial NLR in 309 newly diagnosed MM patients whom treated upfront with novel agents in a retrospective fashion. 37% of their cohort received high-dose therapy followed by autologous stem cell transplantation (ASCT) as consolidation. A $\text{NLR} \geq 2$ was correlated with inferior estimated PFS and OS rates among non-elderly (<65 years) MM patients in all ISS stages and those patients underwent ASCT. In contrast, NLR values did not add any significant impact on long-term survival parameters for elderly MM patients. Despite the upfront administration of novel and more efficient therapies, the results were found to be less promising. Romano *et al.* have reported their 5-year estimated PFS and OS rates, respectively, 18.2% and 36.4% for MM patients with $\text{NLR} \geq 2$ versus 25.5% and 66.6% for patients with $\text{NLR} < 2$.

The authors have also provided a new model including both NLR and ISS staging, "ISS-NLR", and they have limited the deeper analyses for non-elderly MM patients. They have reported that NLR-ISS was able to predict PFS and OS rates in very-low, standard, and very-high risk subgroups, while ISS only was unable. This new model may provide a cost-effective and sustainable prognostic parameter in newly diagnosed MM patients especially in countries where cytogenetic analyses are not available in daily clinical practice. Additionally, a higher NLR did not correlate with the type of induction regimen (based on proteasome inhibitors, immunomodulator agents, or combined) or an adverse karyotype. The authors have also stated that initial cytogenetic analyses were available for 54% of patients and adverse chromosomal abnormalities were observed in 17% of the cases (detailed data not presented) [38].

As a result, novel and available predictors of long-term survival in newly diagnosed MM patients are encouraged in order to better evaluate the risk profile of these patients in the era of novel anti-myeloma agents.

PERIPHERAL T-CELL LYMPHOMA

Recently, Beltran *et al.* retrospectively evaluated 83 peripheral T-cell lymphoma unspecified (PTCL-U) patients in terms of NLR [39]. In multivariate analyses, a NLR ≥ 4 was independently associated with worse OS after adjustment for the IPI score and the Prognostic Index for PTCLU (PIT) score.

CONCLUSION

NLR, seems to be a promising prognostic tool for predicting long-term results in lymphoproliferative hematologic malignancies. Further and comprehensive prospective studies are needed in order to better understand and interpret the exact role of NLR in these complex disorders. These efforts will also provide further therapeutic insights for clinicians.

REFERENCES

- [1] Zahorec R. Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill. *Bratisl Lek Listy* 2001; 102: 5-14.
- [2] Templeton AJ, McNamara MG, Šeruga B, *et al.* Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. *J Natl Cancer Inst* 2014; 106: dju124. <http://dx.doi.org/10.1093/jnci/dju124>
- [3] Porrata LF, Ristow K, Habermann T, Inwards DJ, Micalef IN, Markovic SN. Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. *Am J Hematol* 2010; 85: 896-9. <http://dx.doi.org/10.1002/ajh.21849>
- [4] Park JJ, Jang HJ, Oh IY, *et al.* Prognostic value of neutrophil to lymphocyte ratio in patients presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Am J Cardiol* 2013; 111: 636-42. <http://dx.doi.org/10.1016/j.amjcard.2012.11.012>
- [5] Kwon JH, Jang JW, Kim YW, *et al.* The usefulness of C-reactive protein and neutrophil-to-lymphocyte ratio for predicting the outcome in hospitalized patients with liver cirrhosis. *BMC Gastroenterol* 2015; 15: 146. <http://dx.doi.org/10.1186/s12876-015-0378-z>
- [6] Posul E, Yilmaz B, Aktas G, Kurt M. Does neutrophil-to-lymphocyte ratio predict active ulcerative colitis? *Wien Klin Wochenschr* 2015; 127: 262-5. <http://dx.doi.org/10.1007/s00508-014-0683-5>
- [7] Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. *Semin Cancer Biol* 2012; 22: 33-40. <http://dx.doi.org/10.1016/j.semcancer.2011.12.005>
- [8] Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. *Nature* 2008; 454: 436-44. <http://dx.doi.org/10.1038/nature07205>
- [9] Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. *Cell* 2010; 140: 883-99. <http://dx.doi.org/10.1016/j.cell.2010.01.025>
- [10] Balkwill F. Tumour necrosis factor and cancer. *Nat Rev Cancer* 2009; 9: 361-71. <http://dx.doi.org/10.1038/nrc2628>
- [11] Harrison ML, Obermueller E, Maisey NR, *et al.* Tumor necrosis factor as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. *J Clin Oncol* 2007; 25: 4542-9. <http://dx.doi.org/10.1200/JCO.2007.11.2136>
- [12] Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. *Cancer Res* 2001; 61: 4756-60.
- [13] Rotondo R, Barisione G, Mastracci L, *et al.* IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer. *Int J Cancer* 2009; 125: 887-93. <http://dx.doi.org/10.1002/ijc.24448>
- [14] Zea AH, Rodriguez PC, Atkins MB, *et al.* Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. *Cancer Res* 2005; 65: 3044-8.
- [15] Jodele S, Chantrain CF, Blavier L, *et al.* The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. *Cancer Res* 2005; 65: 3200-8.
- [16] Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. *J Clin Invest* 2008; 118: 1367-79. <http://dx.doi.org/10.1172/JCI33775>
- [17] Scapini P, Morini M, Tecchio C, *et al.* CXCL1/macrophage inflammatory protein-2-induced angiogenesis *in vivo* is mediated by neutrophil-derived vascular endothelial growth factor-A. *J Immunol* 2004; 172: 5034-40. <http://dx.doi.org/10.4049/jimmunol.172.8.5034>
- [18] Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. *N Engl J Med* 1998; 339: 1506-14. <http://dx.doi.org/10.1056/NEJM199811193392104>
- [19] Alvaro-Naranjo T, Lejeune M, Salvadó-Usach MT, *et al.* Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients. *Leuk Lymphoma* 2005; 46: 1581-91. <http://dx.doi.org/10.1080/10428190500220654>
- [20] Schreck S, Friebe D, Buettner M, *et al.* Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. *Hematol Oncol* 2009; 27: 31-9. <http://dx.doi.org/10.1002/hon.878>
- [21] Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. *Blood* 2002; 99: 4283-97. <http://dx.doi.org/10.1182/blood-2002-01-0099>
- [22] Foss HD, Herbst H, Gottstein S, Demel G, Araujo I, Stein H. Interleukin-8 in Hodgkin's disease: preferential expression by reactive cells and association with neutrophil density. *Am J Pathol* 1996; 148: 1229-36.
- [23] Koh YW, Kang HJ, Park C, *et al.* Prognostic significance of the ratio of absolute neutrophil count to absolute lymphocyte count in classic Hodgkin lymphoma. *Am J Clin Pathol* 2012; 138: 846-54. <http://dx.doi.org/10.1309/AJCPO46GFKGNXCBR>
- [24] Lai GG, Lim ST, Tao M, Chan A, Li H, Quek R. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. *Am J Hematol* 2009; 84: 414-7. <http://dx.doi.org/10.1002/ajh.21420>
- [25] Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor (kappa)B signaling pathway in non-Hodgkin's lymphoma B-cell lines: Role in sensitization to chemotherapeutic drug-induced apoptosis. *Cancer Res* 2005; 65: 264-76.
- [26] Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B non-Hodgkin's lymphoma through inhibition of the interleukin 10

- autocrine/paracrine loop and down regulation of Bcl-2 and sensitization of cytotoxic drugs. *Cancer Res* 2001; 61: 5137-44.
- [27] Troppan K, Deutsch A, Gerger A, *et al.* The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma. *Br J Cancer* 2014; 110: 369-74.
<http://dx.doi.org/10.1038/bjc.2013.763>
- [28] Kearn B, Ha H, Kim TM, *et al.* Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. *Leuk Lymphoma* 2015; 56: 2032-8.
<http://dx.doi.org/10.3109/10428194.2014.982642>
- [29] Chang C, Wu SY, Kang YW, *et al.* High levels of regulatory T cells in blood are a poor prognostic factor in patients with diffuse large B-cell lymphoma. *Am J Clin Pathol* 2015; 144: 935-44.
<http://dx.doi.org/10.1309/AJCPUJGMVV6ZF4GG>
- [30] Ho CL, Lu CS, Chen JH, Chen YG, Huang TC, Wu YY. Neutrophil/lymphocyte ratio, lymphocyte/monocyte ratio, and absolute lymphocyte count/absolute monocyte count prognostic score in diffuse large B-cell lymphoma: Useful prognostic tools in the Rituximab era. *Medicine (Baltimore)* 2015; 94: e993.
<http://dx.doi.org/10.1097/MD.0000000000000993>
- [31] Melchardt T, Troppan K, Weiss L, *et al.* Independent prognostic value of serum markers in diffuse large B-cell lymphoma in the era of the NCCN-IPI. *J Natl Compr Canc Netw* 2015; 13: 1501-8.
- [32] Bladé J, Rosiñol L, Cibeira MT. Prognostic factors for multiple myeloma in the era of novel agents. *Ann Oncol* 2008; 19(Suppl 7): vii117-20.
<http://dx.doi.org/10.1093/annonc/mdn437>
- [33] Greipp PR, San Miguel J, Durie BG, *et al.* International staging system for multiple myeloma. *J Clin Oncol* 2005; 23: 3412-20.
<http://dx.doi.org/10.1200/JCO.2005.04.242>
- [34] Neben K, Jauch A, Bertsch U, *et al.* Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. *Haematologica* 2010; 95: 1150-7.
<http://dx.doi.org/10.3324/haematol.2009.016436>
- [35] Avet-Loiseau H, Durie BG, Cavo M, *et al.* Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. *Leukemia* 2013; 27: 711-7.
<http://dx.doi.org/10.1038/leu.2012.282>
- [36] Moreau P, Cavo M, Sonneveld P, *et al.* Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. *J Clin Oncol: Off J Am Soc Clin Oncol* 2014; 32: 2173-80.
<http://dx.doi.org/10.1200/JCO.2013.53.0329>
- [37] Kelkitli E, Atay H, Çilingir F, *et al.* Predicting survival for multiple myeloma patients using baseline neutrophil/lymphocyte ratio. *Ann Hematol* 2014; 93: 841-6.
<http://dx.doi.org/10.1007/s00277-013-1978-8>
- [38] Romano A, Parrinello NL, Consoli ML, *et al.* Neutrophil to lymphocyte ratio improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents. *Ann Hematol* 2015; 94: 1875-83.
<http://dx.doi.org/10.1007/s00277-015-2462-4>
- [39] Beltran BE, Aguilar C, Quinoñes P, *et al.* The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified. *Leuk Lymphoma* 2015; 19: 1-5.
<http://dx.doi.org/10.3109/10428194.2015.1045897>

Received on 17-12-2015

Accepted on 08-01-2016

Published on 20-01-2016

<http://dx.doi.org/10.15379/2408-9877.2016.03.01.03>

© 2016 Burak Uz; Licensee Cosmos Scholars Publishing House.

This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.